Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) involves transecting the hepatic parenchyma and ligating the ipsilateral portal vein to induce the rapid hypertrophy of the contralateral future liver remnant (FLR) until an adequate volume is achieved. Following this, a two-stage hepatectomy of the ipsilateral lesion and liver is performed to prevent postoperative hepatic insufficiency or liver failure resulting from an inadequate FLR. Conventional hepatectomy requires preserving an adequate FLR to ensure postoperative safety. Therefore, conventional hepatectomy is unfeasible in cases where the FLR is insufficient because of the presence of multiple sporadic tumors or giant tumors. Thanks to its distinctive features, the ALPPS procedure overcomes the limitations of conventional hepatectomy, thereby expanding the indications for surgical treatment of liver tumors. Nonetheless, the ALPPS procedure entails high perioperative complication and mortality rates due to its aggressive nature, as evidenced by a reported perioperative complication rate of 68% in an early multicenter study [1]. As the ALPPS procedure becomes increasingly prevalent in clinical settings, major centers have amassed substantial expertise and achieved conceptual and technological improvements, e.g., improvements in indication selection, surgical procedures (e.g., refinement of hepatic transection techniques in stage 1 surgery, and introduction of minimally invasive techniques), and capture of timing for stage 2 surgery, providing a robust basis for lessening the incidence of perioperative complications associated with the ALPPS procedure. In addition, researchers from major centers become increasingly proficient in implementing ALPPS.